Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $3.85 billion. The enterprise value is $3.48 billion.
| Market Cap | 3.85B |
| Enterprise Value | 3.48B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 90.57 million shares outstanding. The number of shares has increased by 19.78% in one year.
| Shares Outstanding | 90.57M |
| Shares Change (YoY) | +19.78% |
| Shares Change (QoQ) | +3.79% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 88.26% |
| Float | 74.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.71 |
| Forward PS | 7.22 |
| PB Ratio | 27.47 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.43 |
| Quick Ratio | 2.09 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -425.60% and return on invested capital (ROIC) is -321.00%.
| Return on Equity (ROE) | -425.60% |
| Return on Assets (ROA) | -45.90% |
| Return on Capital (ROIC) | -321.00% |
| Revenue Per Employee | $346,854 |
| Profits Per Employee | -$480,683 |
| Employee Count | 1,276 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.61 |
Taxes
| Income Tax | -1.87M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.34% in the last 52 weeks. The beta is 0.56, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -2.34% |
| 50-Day Moving Average | 41.25 |
| 200-Day Moving Average | 42.86 |
| Relative Strength Index (RSI) | 51.61 |
| Average Volume (20 Days) | 899,960 |
Short Selling Information
The latest short interest is 4.24 million, so 4.68% of the outstanding shares have been sold short.
| Short Interest | 4.24M |
| Short Previous Month | 5.04M |
| Short % of Shares Out | 4.68% |
| Short % of Float | 5.72% |
| Short Ratio (days to cover) | 3.77 |
Income Statement
In the last 12 months, RARE had revenue of $442.59 million and -$613.35 million in losses. Loss per share was -$7.95.
| Revenue | 442.59M |
| Gross Profit | 392.10M |
| Operating Income | -581.10M |
| Pretax Income | -615.22M |
| Net Income | -613.35M |
| EBITDA | -585.60M |
| EBIT | -615.22M |
| Loss Per Share | -$7.95 |
Balance Sheet
The company has $412.08 million in cash and $40.76 million in debt, giving a net cash position of $371.32 million or $4.10 per share.
| Cash & Cash Equivalents | 412.08M |
| Total Debt | 40.76M |
| Net Cash | 371.32M |
| Net Cash Per Share | $4.10 |
| Equity (Book Value) | 140.26M |
| Book Value Per Share | 1.55 |
| Working Capital | 350.39M |
Cash Flow
In the last 12 months, operating cash flow was -$508.67 million and capital expenditures -$22.44 million, giving a free cash flow of -$531.11 million.
| Operating Cash Flow | -508.67M |
| Capital Expenditures | -22.44M |
| Free Cash Flow | -531.11M |
| FCF Per Share | -$6.30 |
Margins
Gross margin is 88.59%, with operating and profit margins of -131.30% and -138.58%.
| Gross Margin | 88.59% |
| Operating Margin | -131.30% |
| Pretax Margin | -139.00% |
| Profit Margin | -138.58% |
| EBITDA Margin | -132.31% |
| EBIT Margin | -139.00% |
| FCF Margin | -120.00% |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.78% |
| Shareholder Yield | -19.78% |
| Earnings Yield | -15.92% |
| FCF Yield | -13.78% |
Analyst Forecast
The average price target for RARE is $86.60, which is 103.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $86.60 |
| Price Target Difference | 103.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 37.91% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -2.72 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.72 |
| Piotroski F-Score | 2 |